Hester Biosciences growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+6.9%+7.7%
EBITDA+42.0%+19.6%
Net Income+99.5%+27.0%
EPS (adj.)+102.5%+27.8%
Total Assets+3.8%+0.4%
Total Equity+12.6%+8.4%
Free Cash Flow+5.5%—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

HESTERBIO₹2,243.70

Hester Biosciences Limited

· Pharma & Health
₹ CrorePeersWINDLASSYNCOMFNGLFINEINDOCOSAIPARENTJAGSNPHARMPANACEABIOMcap ₹1,909 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+6.9+7.7
EBITDA+42.0+19.6
Net Income+99.5+27.0
EPS (adj.)+102.5+27.8
Total Assets+3.8+0.4
Total Equity+12.6+8.4
Free Cash Flow+5.5—
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.